Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$1.17 - $1.92 $11,408 - $18,721
-9,751 Reduced 34.52%
18,500 $29,000
Q4 2023

Feb 12, 2024

SELL
$0.6 - $1.31 $831,495 - $1.82 Million
-1,385,825 Reduced 98.0%
28,251 $24,000
Q3 2023

Nov 14, 2023

BUY
$1.05 - $3.37 $910,558 - $2.92 Million
867,199 Added 158.57%
1,414,076 $1.51 Million
Q2 2023

Aug 11, 2023

BUY
$2.44 - $4.53 $17,116 - $31,777
7,015 Added 1.3%
546,877 $1.42 Million
Q1 2023

May 18, 2023

BUY
$3.72 - $5.4 $115,212 - $167,243
30,971 Added 6.09%
539,862 $2.2 Million
Q1 2023

May 11, 2023

SELL
$3.72 - $5.4 $214,450 - $311,299
-57,648 Reduced 10.18%
508,891 $2.08 Million
Q4 2022

Feb 13, 2023

BUY
$3.41 - $12.93 $111,309 - $422,061
32,642 Added 6.11%
566,539 $2.85 Million
Q3 2022

Nov 14, 2022

SELL
$12.59 - $17.67 $234,727 - $329,439
-18,644 Reduced 3.37%
533,897 $6.98 Million
Q2 2022

Aug 11, 2022

BUY
$10.58 - $17.5 $196,999 - $325,850
18,620 Added 3.49%
552,541 $7.08 Million
Q1 2022

May 11, 2022

SELL
$13.81 - $18.6 $1.22 Million - $1.65 Million
-88,617 Reduced 14.23%
533,921 $8.14 Million
Q4 2021

Feb 10, 2022

SELL
$17.26 - $22.02 $79,050 - $100,851
-4,580 Reduced 0.73%
622,538 $11 Million
Q3 2021

Nov 12, 2021

BUY
$20.15 - $26.19 $12.6 Million - $16.4 Million
627,118 New
627,118 $13.2 Million

Others Institutions Holding NGM

About NGM BIOPHARMACEUTICALS INC


  • Ticker NGM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 80,365,904
  • Description
  • NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...
More about NGM
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.